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H-Zrestricted cytotoxic T cells specific for Sendai virus were generated in vitro in a 
primary response from normal mouse lymphocytes cultured in the presence of infec- 
tive as well as inactivated Sendai virus. Antigen-presenting cells of different origin, 
including T cells, were found to be effective stimulators. Antibodies to Sendai virus 
were shown to inhibit the activation of specific precursor killer cells when added to 
cultures before, but not after, the addition of viral antigen. Data obtained by Lyt 
phenotyping, revealed that precursor killer cells specific for Sendai virus reside in the 
Lyt-2,3+ T cell population and that Lyt-1,2,3+ T cells are not required for the genera- 
tion of cytotoxic lymphocytes. Different activation kinetics were demonstrated for 
primary and secondary antiviral cytotoxic responses, and the analysis of the prolifera- 
tion and stimulation requirements suggests qualitative differences. 
1 Introduction 
In present models of T cell activation, copresentation of deter- 
minants of the major histocompatibility complex (MHC) and 
viral antigens in the recognition and effector phase is required 
[l]. Activation may therefore be dependent on the tropism of 
viruses for particular cells and the capacity of these cells to 
present viral antigens. Therefore, the role of the presenting 
cells as well as the mode of formation of the new antigenic 
determinant is of special interest. 
If only cell membrane-expressed viral antigens can trigger 
virus-specific cytotoxic T cell (CTL) precursors, the process 
leading to infection and/or membrane expression of viral anti- 
gen acquires a crucial role in T cell activation. Some viruses 
carry in their envelopes the relevant antigenic determinants 
which are expressed on the cell surface immediately after 
virus-cell fusion. In other viral systems, the formation of viral 
determinants on cell membranes requires penetration, uncoat- 
ing and the neosynthesis of proteins. Therefore, the sensitiza- 
tion process of T cells by different viruses may follow different 
activation patterns, 
To establish a model for the study of the activation process in 
vitro, we used the Sendai virus (SV) infection of the mouse. 
Primary T cell activation to SV has recently been reported 
[2, 31. Since SV infection is known to be endemic in many 
mouse colonies [4], emphasis was laid on the question of dis- 
crimination between primary and secondary responses in vitro. 
Using different conditions, we here describe quantitative and 
qualitative differences between primary and secondary CTL 
responses to SV. 
[I 23661 
2 Materials and methods 
2.1 Animals 
BALBk and D B N 2  strain mice were purchased from 
Gl.Bomholtglrd, Ry, Denmark and from the Institut fur Ver- 
suchstierzucht, Hannover, FRG, at 4-8 weeks of age, and 
some of the mice were tested immediately after arrival. B 10, 
B 10.D2, B 10.BR and D B N 2  mice were raised in our own 
breeding facility. 
2.2 Viruses 
SV (kindly provided by Dr. M.-G. Gething, ICRF, London) 
and influenza H virus ANictoria (H 3 N 2) (kindly provided by 
Dr. R. Rott, GieBen, FRG) were grown in 10-day-old embry- 
onated chicken eggs. The allantoic fluid was harvested after 
two days and the viral antigen concentration determined by 
hemagglutination (HA). Purification of SV was obtained by 
centrifugation through a sucrose gradient [20-55 % w/v in 
phosphate-buffered saline (PBS)] . The virus-containing band 
was collected and concentrated by centrifugation at 
120 000 x g for 1 h. Inactivation was achieved by incubating 
the purified virus [2 mg/ml, ca. 4 x lo4 hemagglutinating units 
(HAU) per ml] for 18 h at 4°C with p-propiolactone (p-PL, 
Sigma, Munchen, FRG) at a concentration of 0.025%. p-PL 
was inactivated by incubation for 30 min at 37°C. Inactivation 
was tested by egg infectivity titration. Viruses were stored at 
- 70 "C. 
2.3 Immunization 
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Mice were injected intraperitoneally (i.p.) with 100 HAU of 
infective virus. Lymphocytes from spleen and lymph nodes 
were removed 3-10 weeks afterwards and analyzed in vitro. 
2.4 Media 
Cytotoxic lymphocytes were generated in RPMI 1640 sup- 
plemented with L-glutamine (2 mM final concentration), strep- 
tomycin and penicillin (50 units/ml), 2-mercaptoethanol 
(2 X lOP5M) and 10% fetal calf serum. 
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2.5 Antisera 
Antiserum to SV was raised in DBA/2 mice by 3 weekly i.p. 
injections of 100 HAU. Serum was obtaind 5 days after the 
final injection and tested in hemagglutination inhibition (HAI) 
and an enzyme-linked immnosorbent assay (ELISA). This test 
is based on antibody binding to viral antigen which is coupled 
to plastic surfaces. In a second step, the bound antibody binds 
horseradish peroxydase-coupled viral antigen. Binding of 
enzyme-coupled antigen is then demonstrated by the addition 
of substrate.* Antibody titer to SV was 2.5 x (HAI) and 
3.5 X (ELISA). Antiserum to influenza A substrain Vic- 
toria (H3 N 2) was prepared in a similar way. The titer in HA1 
was 2 x 
AKR anti-C3H antiserum was kindly provided by Dr. B. 
Rubin, Statens Seruminstitut, Copenhagen, Denmark. Anti- 
Lyt antisera were prepared as described by Shen et al. [5]. 
Briefly, anti-Lyt-1.1 antisera were prepared by injecting 
(BALB/c x C 57 BL/6) F1 hybrids with thymocytes from B 6 
Lyt-1.1 congenic mice (Lyt phenotype 1.1,2.2,3.2). Anti-Lyt- 
2.1 antisera were prepared by injecting B 6(H-2k) mice with 
thymocytes from (B 6 x CE) F2 mice homozygous for the Lyt- 
2.1 allele. After one subcutaneous injection of 
50 x lo6 - 100 x lo6 donor cells and three additional i.p. injec- 
tions of 50 x lo6 - 100 x lo6 donor cells at 14-day intervals, 
each mouse was tested individually and only those selected for 
further immunization that produced good specific titers after 
removal of autoantibodies by absorption on thymocytes from 
the recipient strains. Selected mice were bled on day 7 and 10 
after each inoculation, and the sera from several bleedings 
were pooled and stored at - 70°C. Prior to use, the anti-Lyt 
antisera were absorbed once with 100 X lo6 thymus and lymph 
node cells from the recipients and the B 6 congenic strains per 
ml undiluted antisera to remove autoantibodies. In a microcy- 
totoxicity test, the titer of anti-Lyt-1.1 was 1 : 1224 on thymo- 
cytes of B 6 Lyt-1.1 congenic mice, and the titer of anti-Lyt-2.1 
was 1 : 250 on thymocyts of B 6 Lyt-2.1 congenic mice after the 
absorption of autoantibodies. The anti-Lyt-1.1 antiserum was 
used at a dilution of 1 : 40, the anti-Lyt-2.1 antiserum at a final 
dilution of 1 : 10. 
Cells were suspended at a concentration of 3 x lo7 cells/ml and 
treated with anti-Lyt or anti-Thy-1.2 antiserum (at a final con- 
centration of 1: 10) in RPMI 5% fetal calf serum and incu- 
bated for 30 min at room temperature. Cells were centrifuged 
and resuspended in freshly thawed selected rabbit serum (dilu- 
tion 1 : 11) as a source of complement and incubated for an 
additional period of 30 min at 37°C. The treatment of cells 
with anti-Lyt antisera and complement (C) was repeated once. 
Cells were then washed, counted and resuspended to the 
desired concentration. 
2.6 Glutaraldehyde treatment 
Glutaraldehyde treatment of stimulator cells was essentially as 
described by Lightbody and Kong [6]. Cells were washed twice 
in PBS, pH 7.4; lo7 cells were resuspended in 1 ml of 0.025% 
glutaraldehyde (Art. 4239, Merck, Darmstadt, FRG) diluted 
in PBS and incubated with occasional shaking for 20 min at 
20 "C. The cells were subsequently centrifuged (200 X g) and 
washed 3 times with PBS. 
* H. C .  J. Ertl, W. Gerlich and U. H. Koszinowski, manuscript sub- 
mitted. 
2.7 Cell cultures 
P 815 (H-2d), AKR-A (H-2k) and EL 4 (H-2b) tumor cells were 
grown in medium at a concentration of 2 x lo5 cells/ml with 
medium change every 48 h. Mouse spleen cells or lymph node 
cells were suspended in medium at a concentration of 4 X lo6 
cells/ml. Cells were cultured in multi-dish culture trays (FB- 
24Tc, Linbro Chemicals, New Haven, CT) or in plastic tissue 
culture flasks of various sizes. If desired, cells were depleted of 
erythrocytes by lysis in 0.184 M NHdCl or by separation on a 
Ficoll-Hypaque gradient. B cell depletion was achieved by 
nylon wool column passage [7]. Macrophages and adherent 
cells were removed by passage of cells through Sephadex G-10 
columns. Phagocytic cells in the cultures were destroyed by 
addition of 100 pg silica/ml (kindly provided by Dr. Lemke, 
Institut fur Genetik, Koln, FRG) [8]. 
2.8 Stimulator cells 
Various stimulator cells (tumor cells, concanavalin A (Con A) 
blasts, or spleen cells depleted of erythrocytes) were incubated 
with lo2 HAU/106 cells or 1 pg SV protein/106 cells in a volume 
of lo7 cellsiml for 1 h at 37°C. In order to inhibit proliferation 
of the stimulator cells, the virus-containing medium was also 
supplemented with mitomycin C at a concentration of 50 pg/ 
ml. Thereafter, cells were washed 3 times with responder cells 
at various responder-to-stimulator cell ratios. 
2.9 'lCr release assay 
Target cells were incubated with either 10 pg P-PL-inactivated 
SV/106 target cells or with I d  HAU infective SV for 1 h at 
37°C. Labeling with 51Cr was performed at the same time. 
After washing the target cells 3 times, they were incubated at 
1 x lo4 cells/well together with 4 concentrations of attacker 
cells in round-bottomed microtiter plates (Linbro IS-MRC 
96). Spontaneous release was determined by incubating target 
cells in the presence of medium without addition of effector 
cells. Maximum release was determined by addition of 2% 
sodium dodecyl sulfate in PBS. After 4 h incubation at 37 "C in 
5% COZ atmosphere, supernatants were harvested and 'lCr 
release counted in a gamma counter. Data are expressed as 
"Cr release according to the formula: 
% "Cr release = x 100 
Specific release was obtained by subtraction of release by cells 
cultured without antigens from release obtained from specifi- 
cally stimulated cells. 
All values are the mean percent specific 'lCr release of tripli- 
cate wells. Standard errors of the means were always less than 
2 5% and are omitted from the figures for clarity. Lytic units 
(LU) [9] were calculated from four attacker : target cell ratios 
with a Hewlett Packard 67 pocket calculator, using a logarith- 
mic curve fit program. 
"Cr release by immune cells - spontaneous "Cr 
release 
Maximal release - spontaneous release 
3 Results 
3.1 In vitro generation of primary SV-specific CTL by infected 
It has been shown before that virus-specific T cells from 
immune animals can be activated by restimulation with anti- 
and virus-coated stimulator cells 
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Table 1. Induction of SV-specific CTL in vitro") 
(A) Stimulator cellsb) R : S Virus % Spec. release from 
ratio infected P 815') 
50 K : T  10 
ratio 
DBAn macrophages 10: 1 Inf. SV 
P815 20: 1 Inf. SV 
DBAn Con A blasts 10: 1 Inf. SV 
DBAQ spleen cells 10: 1 Inf. SV 
p-PL-sv 
p-PL-sv 
p-PL-sv 
p-PL-sv 
69 
65 
83 
70 
78 
65 
50 
58 
35 
40 
54 
38 
40 
28 
22 
10 
(B) No stimulator cells pg virudml medium (inactivated, 
purified virus) 
10 40 1 1  
1 54 25 
0.1 68 46 
0.01 60 35 
Nil 14 3 50 
vitro responses was used. Responder cells were incubated for 6 
days with stimulator cells pretreated with either infective or 
inactivated SV. It is shown in Table 1 A that effector cells can 
be generated by using as stimulators various cell sources 
including macrophages, lymphocytes, Con A-activated blasts 
and tumor cells. 
H-2 restriction and specificity for viral antigens of these 
cytotoxic lymphocytes generated in vitro were tested with 
spleen cells from strains B 10, B 10.Br and B 10.D 2 and com- 
pared to secondary antiviral cytotoxic responses. It is clearly 
shown in Table 2 that H-2 restriction and specificity for viral 
antigens seen in secondary cytotoxic responses [ 131 is also true 
for primary effector T cells. 
Treatment of primary virus-specific CTL with anti-Thy-1.2 
antiserum and C eliminated the cytolytic activity (Fig. 1). 
Therefore, antiviral CTL are clearly defined as T cells. 
Responder cells obtained from a pool of 5 unprimed DBA/2 mice, 
negative for antibodies to SV. The test was performed after 6 days 
Stimulator cells were incubated for 1 h with 100 HAU of infective 
or inactivated virus followed by 3-fold washing and treatment with 
Percent specific 'lCr release from SV-infected targets over a 
period of 4 h. Four killer-to-target (K:T) ratios were tested (only 2 
given in the table). Means of triplicates are given. SE of means did 
not exceed 5%. 
- 
of culture. 2 
mitomycin C. r .z 
& 
& 
'- 
v, 
0 .- 
Table 2. MHC and virus specificity of primary anti-SV effector cells 
Effector cells"' Target cellsb) 
P815- P815- AKR- AKR- EL4- EL4- 
SV Infl. A A Infl. SV Infl. 
B10.D2 SV" 80 22 3 5 18 18 
B10.D2 INFL.d) 12 74 6 6 8 1 1  
Bl0.BR SV 16 17 36 4 12 12 
BlO.BR INFL. 10 14 6 28 6 8 
B 10. sv 15 18 9 7 76 20 
B 10. INFL. 13 14 0 5 15 64 
a) Ratio effector : target cells = 20 : 1; 4-h 51Cr release assay. 
b) Target cells were obtained after incubation of 100 HAU A Vic- 
toria/106 target cells for 4 h. Spontaneous release from target cells: 
P815-SV: 11%; P815-Infl: 14%; AKR-A-SV: 4%,  AKR-A-Infl: 
4%; EL4-SV: 6%, EL4-Infl: 8%. 
c) Primary cytotoxic response to SV in vitro. 
d) Influenza-specific effector cells were generated by priming of mice 
with 100 HAU influenza A Victoria (H3N2) and secondary 
stimulation in vitro 3 weeks later with medium containing 1-5 
HAU A Victoria/ml. 
gen in vitro [lo-121. The lytic activity of the population in 
which CTL are generated during a secondary response on 
virus-infected target cells is about 100-fold higher in terms of 
cytolytic activity than that of immune T cells tested 7 days after 
infection of animals. For the induction of primary CTL from 
unprimed animals, a protocol similar to that of secondary in 
i 
-0-0 
, 
I I I I 
80 25 12 6 
'12366.11 K:T ratio 
Figure 1 .  Effect of treatment with anti-Thy-1.2 antiserum and C upon 
virus-specific CTL. Equal numbers of SV-specific DBAJ2 effector cells 
generated in a primary in vitro response were pretreated with C alone 
(0), with anti-Thy-1.2 (m) or with anti-Thy-1.2 and C (0) as described 
in Sect. 2. Target cells were P815-SV. 
3.2 Generation of effector cells by addition of viral antigens to 
the in vitro culture 
The fact that cells from different sources were equally effective 
as stimulators suggested that the target antigens required for 
the activation of T cells are not generated by interaction of 
virus with one particular stimulator cell type only. Therefore, 
in the next step, infective (data not shown) or inactivated virus 
(Table 1B) was added directly to the responder cell popula- 
tion. The data demonstrate that virus-specific CTL can be 
generated from spleen cell populations incubated for 6 days 
with inactivated virus. 
3.3 Effect of antibodies to SV on the induction of a cytotoxic 
From the previous findings, we concluded that the virus added 
to the responder cell population probably fuses to cells within 
response 
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this population. This fusion process seems to take place very 
rapidly since incubation of responder cells for 20 min at 37 "C 
with 0.1 pg/ml inactivated purified SV, followed by intensive 
washing, resulted in the generation of CTL (Fig. 2). Since it is 
known that antiviral sera block virus-cell fusion, it was now of 
interest to test whether pretreatment of inactivated SV with 
antibodies would interfere with the induction of CTL. There- 
fore, antibodies specific for SV and antibodies specific for 
influenza virus as a specificity control were added to responder 
cells together with virus. It is illustrated in Fig. 2 that the 
simultaneous addition of virus plus specific antibodies to the 
cell culture did not result in the generation of virus-specific 
killer cells. One could argue that the failure to induce 
cytotoxic T cells is due to blocking of all relevant antigenic 
determinants on the virus by the antibody. We therefore 
tested whether antibodies to SV were able to inhibit the induc- 
tion of killer cells in responder populations preincubated with 
virus. The data show that, once the viral antigens are mem- 
brane-associated, antibodies seem not to be able to inhibit the 
process of T cell activation. These results support the view that 
intimate virus-cell interactions, probably virus-cell fusion, 
induces the formation of new antigenic determinants. This 
process of virus-cell interactions can obviously be inhibited by 
antibodies to SV. The reason for the inability of anti-SV anti- 
bodies to interfere with the activation process after preincuba- 
tion of cells with virus is unclear. It is possible that the deter- 
minants recognized by the antibodies are irrelevant for T cell 
triggering or that the antibody concentration used in the inhi- 
- 
50 15 5 1.6 
-236.21 K:T ratio 
Figure 2. Effect of SV antibodies on CTL induction. (a) Responder 
cells from a pool of 5 DBN2 mice were cultivated in the presence of 
0.1 pg inactivated SV/ml and tested for specific lysis on P815 cells 
infected with SV and uninfected control. Release on uninfected 
targets is subtracted (W). (b) Responder cells incubated with virus for 
20 min followed by 3-fold washing and culture in antigen-free medium 
(0). (c) Culture in presence of antiserum to SV (final dilution 1 : 50) 
and viral antigen as in (a) (+). (d) Culture in presence of antiserum to 
influenza A Victoria virus (H 3 N 2) (final dilution 1 : 50) and viral 
antigen (V). (e) Responder cells incubated with viral antigens for 2 h 
followed by washing as in (b), then addition of antiserum to SV as in 
(C> (4' 
bition experiments was too low to block all determinants 
responsible for the activation of precursor T cells. 
3.4 In vitro primary responses of lymphocytes from different 
origins 
Cells from different lymphoid organs were tested for their 
ability to generate virus-specific CTL (Fig. 3). Lymph node 
and spleen cells were found to be similarly active. Lympho- 
cytes from the thymus could not be activated by viral antigen 
to generate T killer cells. To demonstrate possible inhibitory 
or amplifying properties of thymus cells, cell mixing experi- 
ments were carried out. As can be seen in Fig. 3, there was no 
detectable help or  inhibition by thymus cells regarding genera- 
tion of T killer cells in spleen and lymph node cell populations 
under the experimental conditions used. 
Figure 3. Induction of CTL in cultures of cells from different lym- 
phoid organs. Four x lo6 cells/ml from DBM2 mice were cultured in 
the presence of medium containing 0.1 pg P-PL-inactivated SV/ml for 
5 days. Activity is tested in triplicate at different killer-to-target cell 
ratios on '*Cr labeled P 815 SV (0) and uninfected P 815 (0) cells in a 
4-h assay. (I) Spleen cells; (11) peripheral lymph node cells; (111) thy- 
mus cells; (IV) mixture of spleen and thymus cells 1 : 1; (V) mixture of 
lymph node and thymus cells 1 : 1. 
The data described so far show that there is no requirement for 
a particular stimulator cell in the generation of CTL, but that 
viral antigens are only sensitizing when they are associated 
with the cell membrane. Since in these experiments, 
unselected lymphocyte populations were used, it was now of 
interest to test whether there are limiting responder cell 
requirements in the generation of viral specific CTL. We 
therefore tested T cells selected by nylon wool, or T cells 
depleted in addition of macrophages by Sephadex G-10 col- 
umn separation. The macrophage-depleted T cell population 
was also sensitized in vitro to antigens in the presence of silica, 
which is known to be an agent selectively toxic for mac- 
rophages without reducing the viability of lymphocytes in vitro 
[8, 141. All the populations were able to generate a cytotoxic 
response to SV (Fig. 4). Although we cannot formally exclude 
antigen presentation on macrophages, the probability is slight 
that a phagocytic cell is required as antigen-presenting cell. 
This suggests that the T cell is not only the responder cell but 
can also act as stimulator cell in the generation of antiviral T 
killer cells. 
3.5 Lyt phenotype of the primary T killer cell precursors 
In order to investigate the type of T cells that participate in the 
induction phase of the response to SV antigens, the responder 
cell populations were pretreated with either anti-Lyt-1 or  anti- 
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not required for the generation of H-Zrestricted and virus- 
specific CTL. 
50 15 5 1 
lml K : T  ra t io  
Figure 4. Effect of depletion of adherent and phagocytic cells on the 
induction in vitro of CTL. Culture conditions and cytotoxic test as in 
Fig. 3. (I) Cells separated by nylon wool column; (11) as in (I) plus 
additional separation on Sephadex G-10 column; (111) as in (11) plus 
100 pg/ml silica to cultures. 
50 15 5 1.6 
GI K:T ratio 
Figure 5. Effect of pretreatment of equal numbers of DBN2 spleen T 
cells with Lyt antisera and C prior to culture on the generation of 
primary virus-specific CTL in vitro. No treatment (0); treatment with 
C (m); treatment with anti-Lyt-2.1 and C (V); treatment with anti- 
Lyt-1.1 and C (A); 50% cells treated with anti-Lyt-2.1 and C plus 50% 
cells treated with anti-Lyt-1.1 and C (+). 
Lyt-2 antisera and C (Fig. 5). Both populations were incu- 
bated with antigen either individually or as a combined frac- 
tion containing Lyt-l+ and Lyt-2,3+ but not Lyt-1,2,3+ T cells. 
It is shown in Fig. 5 that Lyt-2,3+ cytotoxic effector cells are 
very efficiently generated from Lyt-2,3+ precursor cells even 
in the absence of Lyt-l+ T cells. This was not always the case 
since in other experiments, Lyt-2,3+ precursor cells required 
the presence of Lyt-l+ T cells for an effective generation of 
CTL. Lyt-l+ T cells were unable to mount a cytotoxic 
response to SV. Obviously, like in other systems, Lyt-l+ T 
cells do not contain precursor killer cells, but the remote possi- 
bility that the result is due to their possible failure to function 
as antigen-presenting cells is still open. These experiments 
show that in contrast to the generation of syngeneic trini- 
trophenyl (TNP)-specific killer cells [15], Lyt-1,2,3+ T cells are 
3.6 Quantitative and qualitative differences between primary 
and secondary T cell responses to SV 
3.6.1 General remarks 
It could be argued that the mice used for primary in vitro 
cultures had already been presensitized in vivo by infection. 
We therefore tested routinely the sera of the mice for anti- 
bodies to paramyxoviruses. This was done by virus neutraliza- 
tion, HA1 and by an ELISA assay in which IgM and IgG 
antibodies to viral antigens can be found to be 100-fold more 
sensitive as compared to HAI. Only animals which showed 
negative results in these tests were used in our experiment. 
Although antiviral antibodies are usually demonstrable for a 
very long time after infection, this does not necessarily imply 
that the absence of a humoral response reflects a virgin state 
with respect to cellular immunity. 
We therefore investigated the kinetics, cytolytic activity, 
responder cell proliferation and stimulator cell requirements 
of primarily in vitro induced virus-specific CTL and compared 
the results with those obtained from in vivo primed spleen cell 
populations activated under identical conditions. 
3.6.2 Kinetics and cytolytic activity 
Cultures were set up with inactivated virus as antigen under 
identical conditions using as responder cells normal DBAl2 
spleen cells or cells from mice primed with either 100 HAU 
infective or inactivated SV. It was found that in primed spleen 
cell populations, CTL can be demonstrated as early as 24 h 
after in vitro culture. In unprimed populations, a comparable 
cytotoxic response was only detectable after 3 days of culture 
(Table 3). Cells from mice primed with infective virus showed 
a 10-fold higher activity in terms of LU compared to unprimed 
animals or animals primed with inactivated virus. In all 3 
groups, the peak responses were found on day 5-8. There was 
Table 3. Kinetics of killer T cell generation in vitro. Cytotoxic activity 
on P 815-SV in LU/106 effector cells 
Sensitization of animals 
Days of in 104 HAU SV i.p. 104 HAU PPL- No sensitization 
vitro cul- SV i.p. in vivo 
tureP) 
1 1.ox 104 6.5 x Id 1.7 x Id 
3 6.0 x l@ 5.1 X 104 5.0 x 10" 
6 
8 
10 
6.9 x 16 5.4 x 104 7.2 x 10" 
1.9 x 104 7.4 x 16 1.8 X 10" 
7.4 x 104 2.2 x Id 2.8 X 16 
13 2.0 x 10s NT 4.6 X 10" 
a) Culture conditions as in Fig. 2. Cultured cells from primed and 
unprimed mice were tested on SV-infected and uninfected P 815 
cells over a period of 13 days. For the sake of brevity, the activities 
are expressed in LU/106 responder cells. 1 LU = ratio attacker-to- 
target cells resulting in 33% specific lysis. Day of peak activity 
underlined. 
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no significant difference between unprimed spleen cells and 
cells primed with inactivated virus besides an earlier onset of 
the cytotoxic response in the primed population. In all 3 cul- 
tures, cytolytic activity was demonstrable up to 3 weeks (data 
not shown). 
"\ . 
3.6.3 Responder cell proliferation requirements 
In the next step, we investigated the requirement of prolifera- 
tion for primary responder cells and compared it to that of a 
secondary antiviral response. For this purpose, untreated cells 
or cells treated with mitomycin C from primed and unprimed 
animals were cultured in the presence of inactivated SV, and 
cytotoxic activity was tested at 24-h intervals. The proliferative 
response was monitored to control the efficiency of mitomycin 
C treatment (data not shown). Cells from sensitized mice 
responded to secondary in vitro stimulus even after pretreat- 
ment with mitomycin C (Fig. 6). However, cells from unsen- 
sitized animals did not respond to SV antigens after mitomycin 
C pretreatment in primary in vitro cultures. Thus, prolifera- 
tion of the responder cell population is an essential require- 
ment for primary but not for secondary cytotoxic immune 
responses to virus in vitro. 
3.6.4 Stimulator cell requirements 
Since it is known from the induction of alloreactive T cells that 
secondary but not primary responses can be obtained with 
fixed stimulator cells or cell fragments [16], we tested whether 
the antiviral T cell generation in vitro is governed by the same 
/ 
0 1 2 3 4  
Days of in vitro culture j12366.61 
5 
Figure 6. Proliferation requirements for the induction of CTL. Cul- 
ture conditions and assay as in Fig. 3. (A) Activity of in vivo sensitized 
and in vitro restimulated DBN2 spleen cells on P815-SV (0) and 
uninfected target cells (0). Same spleen cell population treated previ- 
ous to in vitro culture with 50 pg mitomycin C/106 cells/ml for 45 min. 
P81.5-SV target cells (O), P815 target cells (I). (B) Activity of 
unprimed DBN2 spleen cells after primary sensizitation in vitro. 
Target and responder cell treatment as in (A). 
I 
Figure 7.  Stimulator cell requirements for the induction of CTL. Cul- 
ture conditions and assay as in Fig. 3. (A) Activity of in vivo sensitized 
spleen cells after secondary stimulation in vitro on uninfected P815 
(0 I) or virus-infected P 815 cells (0 0). Effector cells generated in 
the presence of living stimulator cells (0 0) or glutraldehyde-fixed 
stimulator cells (0.). (B) Activity of unprimed DBN2 spleen cells 
after primary sensitization in vitro. Stimulator cell conditions and 
targets as in (A). 
principles. Responder cells from primed and unprimed ani- 
mals were incubated with virus-coated P 815 stimulator cells, 
either glutaraldehyde-fixed or untreated. It is shown in Fig. 7 
that only the primed responder population was able to mount 
a response to both viable and glutraldehyde-fixed virus-coated 
stimulator cells. These results strongly suggest that in a pri- 
mary response to SV in vitro, nonfixed cells are required for 
the appropriate presentation of viral antigen. 
4 Discussion 
In order to analyze the induction phase of antiviral cytotoxic T 
cells on a cellular level, an in vitro system for the generation of 
primary SV-specific killer cells was established. Being aware 
of the fact that many mouse colonies are endemically infected 
with SV [4], the following precautions were taken to exclude 
previously sensitized mice from the experiments. Animals 
from breeding stocks, raised under specific pathogen-free con- 
ditions, were used immediately after arrival, besides our own 
mice, and found to be capable of generating primary cytotoxic 
responses to SV in vitro. In addition, mice were tested for 
antiviral antibodies in sensitive assays (HAU, virus neutraliz- 
ation and ELISA), and only those found to be negative were 
used in this study. Mice, positive for antibodies to SV, reacted 
in accord with the criteria we established for a secondary 
response. Since antiviral antibodies, once generated, could be 
detected for more than 6 months, a previous contact of the 
animals with the antigen is very unlikely,although sensitization 
in a earlier phase cannot formally be excluded. However, the 
differences found in the induction of cellular immune 
responses between mice primed to SV and unsensitized ani- 
mals argue against this possiblity. Furthermore, to circumvent 
this problem, mice of 8-12 weeks of age were used. A com- 
parison of the primary vs. secondary cytotoxic response to SV 
showed a significant difference in the magnitude of the 
immune response (secondary immune response 10-fold higher 
than primary immune response) as well as in the onset of the 
cytotoxic responses (secondary CTL day 1, primary CTL day 
3). In addition, we found that the lymphocyte population from 
primed and unprimed mice differed also with respect to their 
induction requirements. Thus, proliferation was not required 
for the generation of secondary CTL and was essential for the 
generation of primary CTL to SV. Furthermore, it was shown 
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that glutaraldehyde-fixed stimulator cells were only able to 
sensitize virus-specific memory CTL, as found by other inves- 
tigators [lo], but not virus-specific primary CTL. The differ- 
ences observed are not necessarily qualitative because they 
could also be explained in quantitative terms. Since, to our 
knowledge, there is no evidence for clearly defined quantita- 
tive differences between unprimed and primed CTL, our 
criteria for the definition of the virgin state of the precursor T 
cells are therefore as yet functional. 
There are striking similarities between the proliferation and 
activation characteristics of CTL generated in vitro against 
viral antigens and CTL generated in mixed lymphocyte cul- 
tures against alloantigens: (a) peak responses are obtained at 
about day 6-8, after which CTL activity progressively 
decreases but is still demonstrable for periods up to three 
weeks [17]. There is a considerable difference in magnitude 
between primary and secondary responses [16, 181. (b) Pri- 
mary responses require cell proliferation [19,20] while activa- 
tion of memory CTL does not require DNA synthesis [21,22]. 
(c) The conditions of stimulator cells are critical in both sys- 
tems during primary induction of CTL in vitro [23,24] but less 
stringent during secondary stimulation [16, 251. (d) Similar to 
the Lyt phenotype of alloreactive T cell precursors [26], 
cytotoxic precursor cells specific for SV were also shown to 
reside in the Lyt-2,3+ cell pool. 
This conclusion is derived from experiments showing that 
effector cells could be generated from T cell populations 
selected for Lyt-2,3+ T cells and in populations containing Lyt- 
1+ and Lyt-2,3+ T cells which have been depleted from Lyt- 
1,2,3+ T cells. There was no generation of killer cells in cul- 
tures containing Lyt-l+ T cells. From these data, we conclude 
that Lyt-1,2,3+ cells are not necessarily required during the 
induction of H-Zrestricted and virus-specific CTL. This is in 
contrast to the results obtained with H-Zrestricted and TNP- 
specific CTL in which the requirement of Lyt-1,2,3+ T cells in 
the generation of CTL has been shown [15]. 
It is not yet clear whether the precursors of the H-Zrestricted 
T cell populations specific for viral antigen or TNP, respec- 
tively, reside in different T cell pools or whether the Lyt- 
1,2,3+ T cells act as precursor helper cells during the genera- 
tion of T cells specific for haptens but not during the genera- 
tion of virus-specific CTL (M. M. Simon and U. Koszinowski, 
manuscript in preparation). In some experiments, highly 
active CTL could be generated from Lyt-2,3+ T cells while in 
other experiments, Lyt-l+ T cells had an additional amplifying 
effect on the generation of virus-specific killer cells. Further 
experiments will have to show to what extent Lyt-1' helper T 
cells are involved in the generation of antiviral T cell 
responses. These findings reveal further similarities between 
alloreactive and virus-specific H-Zrestricted CTL. They also 
demonstrate that the requirements for T cell subsets in the 
generation of H-Zrestricted CTL are not identical for all anti- 
gens. 
In contrast to activation against SV, primary induction of CTL 
against other viruses tested so far has proven difficult. If the 
SV system turns out to be an exception, one has to be critical 
as to whether the activation process towards paramyxoviruses 
is an example for CTL activation to viruses in general. The SV 
model has some properties in common with other virus models 
while it differs in other respects. Priming with inactivated virus 
and secondary challenge with inactivated virus has been possi- 
ble with SV [2, 13, 27, 281, rabies virus [29] and influenza 
viruses [30,31], but not with vaccinia [32,33] and herpes virus 
([34], M. Rollinghoff, personal communication). Paramyxo- 
viruses are known for their fusion capacity while other viruses 
are less effective in this respect. Investigations on the require- 
ments for target cell formation have shown differences: pox 
virus and herpes virus seem to require insertion of early virus- 
induced antigens to the plasma membrane of the target cell, 
while target cell formation with SV requires neither protein 
synthesis nor the presence of viral RNA [13]. Early antigens 
recognized on target cells infected with pox virus are presum- 
ably nonstructural proteins while in the SV model, the anti- 
gens inducing T cell triggering and target cell formation are 
spike proteins of the viral envelope [13, 27, 321. 
There is little information about the stimulator and responder 
cell requirements during primary induction of antiviral CTL. 
Macrophages are reported to be an essential requirement for 
the secondary in vitro induction of ectromelia virus-specific 
CTL [35]. Furthermore, from data obtained with chimeric 
mice, which showed that cells from parent into F1 chimeras 
could only be induced to generate T killer cells with H-2 
specificity for the other parent in an environment containing 
lymphoid cells expressing the H-2 specificity of that parent, R. 
Zinkemagel [l]  concluded that cells of the lymphoreticular 
system are in fact required for presentation of the viral anti- 
gen. This conclusion is supported by our earlier [ l l ]  and pre- 
sent data since we find that all cells used in the induction 
phase, even T cells can serve as effective stimulator cells, and 
macrophages are not required in the culture. 
Our studies on virus cell interaction suggest that it is mainly 
the viral activity, presumably fusion, which induces the forma- 
tion of the new antigenic determinant and that interference 
with this step will block T cell generation. In this context, it is 
intriguing to speculate that the role of antigen presentation by 
lymphoid cells is primarily dependent on the capacity of a 
given virus to induce the new antigenic determinants on the 
cell surface which is high for SV and low for pox and other 
viruses [36]. The high capacity to induce new antigenic deter- 
minants is explained by the fact that virus with a low multiplic- 
ity of infectivity or even noninfectious virus will create the 
antigenic determinants immediately after virus-cell contact, 
while other viruses, less active in fusion, require either higher 
amounts of viral antigen for immediate antigen expression on 
membranes or even protein neosynthesis. 
Recently, mitogenic activity has been described for some 
strains of influenza viruses [37]. Generation of SV-specific 
CTL with cross-reactive activity on allogeneic target cells has 
been described [38,39]. We found even generation of alloreac- 
tive CTL without cross-reactive properties indicating poly- 
clonal T cell activation by SV (U. Koszinowski, unpublished 
observations). Furthermore, SV is a potent inducer of viral 
interferon. Increased production of interferon has recently 
been observed during mixed lymphocyte culture reactions in 
which CTL were generated [40], but its role in the induction of 
CTL remains open. 
The combined features of SV, namely (a) T cell activation in 
the absence of infectivity, (b) fusion capacity, (c) target cell 
induction by spike proteins, (d) mitogenic activity on T cells 
and (e) induction of interferon, which are intrinsic for certain 
viruses (paramyxoviruses) but not others, might be the reason 
for the possibility to induce primary CTL to SV in vitro. 
722 U. H. Koszinowski and M. M. Simon Eur. J. Immunol. 1979,9: 715-722 
The way by which SV-specific T cell activation occurs is still 
unclear. but it could be described hvootheticallv as follows: 
14 Kessel, R. W. I., Monaco, L. and Marchisio, M. A., Br. J.  Exp. 
Pathol. 1963. 44: 351. 
a 1  
mitogenic activity stimulates several T cell populations, and 
unspecific helper factors are induced [41,42]. Virus fuses with 
cells within the responder cell population which creates the 
specific T cell-activating determinants. The fusion capacity of 
SV might even allow refusion and new presentation when the 
cell-presenting antigens initially deteriorates, which is indi- 
cated by cross-priming and cross-stimulation data in a secon- 
dary response ([ll] and U. Koszinowski, unpublished observa- 
tions). This effect may lead to long-term exposure of SV anti- 
gens on living cells in an immunogenic form. 
Several aspects of this activation process, in particular the 
immunogenicity of the two surface proteins of SV, the 
mitogenic effect, the role of fusion and the H-2 requirements 
during CTL induction are presently under investigation. 
We are grateful to Iris Neuschafer-Rube and Birgit Abenhardt for their 
skillful technical assistance. 
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